Due to the low cost and wide availability of tests, blood eosinophils are considered a suitable biomarker [106], primarily because they predict asthma remission more accurately than specific IgE or skin-prick tests, and their absence was shown to be able to correctly predict more than 91% of remissions [107]. This evidence concerns the gene IGHE and asthma.